A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped It has been determined on June 10th that the 205165 study will not progress. This decision has been made prior to study start, no patients were screened.

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg
DRUG: Fluticasone furoate 100 mcg + Vilanterol 25 mcg
DRUG: Umeclidinium 62.5 mcg
DEVICE: Placebo ELLIPTA inhaler
DRUG: Albuterol/Salbutamol

Sponsor

GlaxoSmithKline